Galapagos NV (ETR:GXE)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.87B +29.7% |
| Revenue (ttm) | 286.92M +10.3% |
| Net Income | -435.96M |
| EPS | -6.62 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 13.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,135 |
| Average Volume | 1,100 |
| Open | 28.34 |
| Previous Close | 28.34 |
| Day's Range | 28.34 - 28.60 |
| 52-Week Range | 24.14 - 32.24 |
| Beta | n/a |
| RSI | 51.14 |
| Earnings Date | Feb 23, 2026 |
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]
Financial Performance
In 2024, Galapagos NV's revenue was 275.65 million, an increase of 14.99% compared to the previous year's 239.72 million. Earnings were 74.08 million, a decrease of -65.01%.
Financial StatementsNews
Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation
Galapagos offers deep value with €3B cash, a focused M&A strategy, and new leadership. Click here to read an analysis of GLPG stock now.
Galapagos (GLPG) Achieves Key Milestone in Dermatomyositis Study
Galapagos (GLPG) Achieves Key Milestone in Dermatomyositis Study
Galapagos NV: Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus
GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary measures of disease activity compared to ...
GLPG Crosses Above Average Analyst Target
In recent trading, shares of Galapagos NV (Symbol: GLPG) have crossed above the average analyst 12-month target price of $32.50, changing hands for $32.57/share. When a stock reaches the target an ana...
Galapagos (GLPG) Showcases Promising Phase 2 Results for CAR T-Cell Therapy
Galapagos (GLPG) Showcases Promising Phase 2 Results for CAR T-Cell Therapy
Galapagos NV: Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell ...
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell the...
Galapagos NV: Galapagos Receives Transparency Notifications from Bank of America
Mechelen, Belgium; November 26, 2025, 07:30 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to Belgian transpa...
Galapagos Receives Transparency Notifications from Bank of America
Mechelen, Belgium ; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America.
Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript
Galapagos NV ( GLPG) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Glenn Schulman Henry Gosebruch - CEO & Executive Director Aaron Cox - Chief Financial Officer Dan Grossman...
Galapagos to Present New Data from Cell Therapy Program at ASH 2025
Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors
Mechelen, Belgium ; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG36...
Biotech firm Galapagos to wind down cell therapy business
Biotechnology firm Galapagos said on Tuesday it would wind down its cell therapy business after attempts to sell it were unsuccessful, affecting 365 jobs in Europe, China and the U.S.
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company's Ongoing Transformation
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos
Galapagos Announces Appointment of Fred Blakeslee as General Counsel
Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective O...
Biotechnology firm Galapagos receives offers for cell-therapy business
Biotechnology firm Galapagos' board has received non-binding offers from consortia, mainly comprised of financial investors, for its cell-therapy business, the company said on Wednesday.
Galapagos Provides Update on Strategic Alternatives for Its Cell Therapy Business
Mechelen, Belgium ; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement:
Galapagos Creates New Subscription Right Plan
Mechelen, Belgium; August 7, 2025, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,800,000 subscription rights under a ...
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the United States Food and Drug Administration (FD...
Galapagos Bolster Leadership Team with Seasoned Life Sciences Executives to Accelerate Business Transformation
Appoints Sooin Kwon as Chief Business Officer and Dan Grossman as Chief Strategy Officer Both executives possess proven track records in strategic execution and deal-making and will help drive long-te...
Galapagos Welcomes Seasoned Pharmaceutical Executives Dawn Svoronos and Jane Griffiths to Its Board of Directors
New Directors bring deep commercial, operational, and transaction experience to the Board Mechelen, Belgium; July 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appoin...
Galapagos Reports Half-Year 2025 Financial Results and Provides Second Quarter Business Update
Appointments of new CEO, CFO, and seasoned business development leaders with proven track records of executing strategic transactions will position the Company to drive shareholder value and advance p...
Galapagos Appoints Aaron Cox as Chief Financial Officer
Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership
Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101
Of the 34 patients enrolled in Cohort 3 of the ATALANTA-1 Phase 1/2 study, 32 received GLPG5101; 94% were infused with fresh CAR-T cells, and 93% were treated within seven days of manufacturing
Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL
Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin's Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities